Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - REJUVEL BIO-SCIENCES, INC.ex31_1apg.htm
EX-32.1 - EXHIBIT 32.1 - REJUVEL BIO-SCIENCES, INC.ex32_1apg.htm
EX-31.2 - EXHIBIT 31.2 - REJUVEL BIO-SCIENCES, INC.ex31_2apg.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________


FORM 10-Q

____________


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014


[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934


For the transition period from ______ to _______


Commission File Number 0-53698


TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION

(Name of small business issuer in its charter)


Florida

 

27-1116025

(State of incorporation)

 

(I.R.S. Employer Identification No.)


18851 N.E. 29th Avenue, Suite 700,

Adventura, Florida 33180

(Address of principal executive offices)


(786) 787-0402

(Registrant’s telephone number)


Copy of all Communications to:

Law Office of Andrew Coldicutt

1220 Rosecrans Street, PMB 258

San Diego, CA 92106

Phone: 619-228-4970

Info@ColdicuttLaw.com


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X]   No [   ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes [X]   No [   ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer

[   ]

Accelerated filer

[   ]

Non-accelerated filer

[   ] (Do not check if a smaller reporting company)

Smaller reporting company

[X]


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [   ]  No [X]


As of May 20, 2014, there were 118,581,119 shares of the registrant’s $0.001 par value common stock issued and outstanding.





TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION*


TABLE OF CONTENTS

 

Page

PART I.  FINANCIAL INFORMATION

 

 

ITEM 1.

FINANCIAL STATEMENTS

3

 

 

 

ITEM 2.

  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

13

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

16

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES    

16

 

 

 

PART II.  OTHER INFORMATION

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

17

 

 

 

ITEM 1A.

RISK FACTORS

17

 

 

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

17

 

 

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

17

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

18

 

 

 

ITEM 5.

OTHER INFORMATION

18

 

 

 

ITEM 6.

EXHIBITS

18




Special Note Regarding Forward-Looking Statements


Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). This information may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Technology Applications International Corporation (the “Company”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies and expectations of the Company, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that these projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.


*Please note that throughout this Quarterly Report, and unless otherwise noted, the words "we,"”TAIC,” “NUUU,” “Renuell Int’l,” “NueEarth,” "our," "us," the "Company," refers to Technology Applications International Corporation.



2



PART I - FINANCIAL INFORMATION


ITEM 1. FINANCIAL STATEMENTS





TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION

(A Development Stage Company)


Condensed Consolidated Financial Statements


(Expressed in US dollars)


March 31, 2014 (unaudited)






Financial Statement Index




Condensed Consolidated Balance Sheets (unaudited)

4

 

 

Condensed Consolidated Statements of Operations (unaudited)

5

 

 

Condensed Consolidated Statements of Cash Flows (unaudited)

6

 

 

Notes to the Condensed Consolidated Financial Statements (unaudited)

7












3




TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEETS

 

 

 

 

 

 

 

 

 

March

31,

 

December

31,

 

 

 

2014

 

2013

ASSETS

 

 

(Unaudited)

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

 $

218,312 

  $

4,891 

Inventories

 

 

88,420 

 

70,862 

Deposits

 

 

7,000 

 

7,000 

Other current assets

 

1,909 

 

1,909 

Total current assets

 

315,641 

 

84,662 

Trademarks, net

 

1,914 

 

1,940 

Machinery and equipment, net

 

 

18,189 

 

19,371 

Total assets

 $

335,744 

  $

105,973 

LIABILITIES AND SHAREHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

Accounts payable and accrued expenses

 

$

351,465 

 $

344,415 

Advances from affiliate

 

 

340,757 

 

237,480 

Loan from affiliate

 

 

77,401 

 

77,401 

Convertible debentures (net of debt discount of $9,611 and $75,902,

respectively)

10,388 

 

198,099 

Derivative liability

 

 

2,557,054 

 

349,940 

 

 

 

 

 

 

Total current liabilities

 

 

3,337,065 

 

1,207,335 

 

 

 

 

 

 

Total liabilities

 

 

3,337,065 

 

1,207,335 

Shareholders' deficit

 

 

 

 

 

Preferred stock, par value, $0.001 per share, 50,000,000 shares

 

 

 

 

 

authorized, none issued or outstanding

 

 

 

Common stock, par value $0.001 par value, 300,000,000 shares authorized,

 

 

 

118,514,615 and 117,348,000 shares issued and outstanding at

 

 

 

 

 

March 31, 2014 and December 31, 2013, respectively.

 

 

118,515 

 

117,348 

Additional paid in capital

 

 

1,139,346 

 

586,199 

Subscription receivable

 

 

(66,500)

 

 

Accumulated deficit

 

 

(4,192,682)

 

(1,804,909)

Total shareholders' deficit

 

 

(3,001,321)

 

(1,101,362)

Total liabilities and shareholders' deficit

 

 $

335,744 

  $

105,973 


The accompanying condensed notes are an integral part of these financial statements



4




TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 

 

 

 

 

 

 

 

Three Months Ended March 31, 2014 and 2013 and Period from October 14, 2009

(Inception of Development Stage) through March 31, 2014

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

Period from October 14, 2009 (inception of development stage) through

 

 

 

2014

 

2013

 

March 31, 2014

 

 

 

 

 

 

 

 

Revenues

 

 

$

2,268 

 

10,047 

 

$

63,306 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

2,920 

 

5,449 

 

$

34,219 

 

 

 

 

 

 

 

 

Gross profit

 

 

(652)

 

4,598 

 

29,087 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

General and administrative

 

 

128,728 

 

138,658 

 

1,621,222 

 

 

 

 

 

 

 

 

Loss From Operation

 

 

(129,380)

 

(134,060)

 

(1,592,135)

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

Gain (loss) on derivative valuation

 

 

(1,926,797)

 

(25,000)

 

(1,785,365)

 Gain on forgiveness of debts

 

 

 

 

1,000 

 Derivative expense

 

 

(251,814)

 

 

(251,814)

Interest expense

 

 

(79,782)

 

(29,374)

 

(564,368)

Total other income (expense)

 

 

(2,258,393)

 

(54,374)

 

(2,600,547)

Net loss

 

 

(2,387,773)

 

(188,434)

 

(4,192,682)

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

Basic and diluted

 

 

($0.02)

 

($0.00)

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares

 

 

 

 

 

 

 

Basic and diluted

 

 

117,742,089 

 

117,248,000 

 

 


The accompanying condensed notes are an integral part of these financial statements



5




TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2014

 

Three months ended March 31, 2013

 

Period from October 14, 2009 (inception of development stage) through March 31, 2014

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

 

 

 

(2,387,773)

 

(188,434)

 

(4,192,682)

Adjustments to reconcile net income to

 

 

 

 

 

 

 

 

net cash used in operating activities:

 

 

 

 

 

 

 

 

Loss (Gain) on derivative valuation

 

 

 

1,926,797 

 

25,000 

 

1,785,365 

Derivative expense

 

 

 

251,814 

 

 

251,814 

Gain on forgiveness of debts

 

 

 

 

 

 

(1,000)

Amortization of discount on convertible debentures

66,289 

 

24,658 

 

512,839 

Depreciation and amortization

 

 

 

1,208 

 

1,020 

 

13,720 

Shares issued for services rendered

 

 

 

 

 

 

11,318 

Change in current assets and current liabilities:

 

 

 

 

 

Accounts receivable

 

 

 

 

(307)

 

Inventory

 

 

 

(17,558)

 

3,139 

 

(88,420)

Deposits

 

 

 

 

(10,000)

 

(7,000)

Other current assets

 

 

 

 

1,852 

 

(1,909)

Accounts payable and accrued expenses

35,367 

 

30,928 

 

380,782 

Other current liabilities

 

12,000 

 

Net cash used in operating activities

 

 

 

(123,856)

 

(100,144)

 

(1,335,173)

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchase of equipment

 

 

 

 

 

(31,553)

Increase in trademarks

 

 

 

 

 

(2,170)

Net cash used in investing activities

 

 

 

 

 

(33,723)

Cash flows from financing activities

 

 

 

 

 

 

 

 

Proceeds from short-term advance

 

 

 

 

 

 

Advances from (to) affiliate, net

 

 

 

114,058 

 

(7,819)

 

505,669 

Proceeds from loan from affiliate

 

 

 

 

 

125,000 

Repayment of loan from affiliate

 

 

 

(10,781)

 

 

(110,711)

Proceeds from issuance of convertible debentures

 

 

 

 

 

324,000 

Proceeds from issuance of common stock

 

 

 

234,000 

 

 

743,250 

Net cash provided by (used in) financing activities

 

 

 

337,277 

 

(7,819)

 

1,587,208 

Net change in cash and cash equivalents

 

 

 

213,421 

 

(107,963)

 

218,312 

Cash and cash equivalents, beginning balance

 

 

 

4,891 

 

120,697 

 

Cash and cash equivalents, ending balance

 

 

 

218,312 

 

12,734 

 

218,312 

Supplemental disclosure of cash flow information

 

 

 

 

 

Income taxes paid

 

 

 

$

 

$

 

$

Interest paid

 

 

 

$

 

$

 

$

Non-cash transactions affecting Operating,

 

 

 

 

 

 

 

     Investing and Financing activities

 

 

 

 

 

 

 

Deposit converted to convertible debenture

 

 

$

 

$

 

$

100,000.00 

Issuance of common stock - shareholder note payable

$

 

$

 

$

101,800.00 

Issuance of common stock for services

 

 

$

 

$

 

$

11,318.00 

Issuance of common stock for convertible notes converted

$

486,983.00 

 

$

 

$

486,983.00 

Subscription receivable

 

 

 

$

66,500.00 

 

$

 

$

66,500.00 


The accompanying condensed notes are an integral part of these financial statements




6




TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

 

 

 

 

 

 

 

 

 

(Notes to the Condensed Consolidated Financial Statements (Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


1.

Nature of Operations and Basis of Presentation


Nature of Operations


Technology Applications International Corporation (formerly Raj Ventures, Inc.) (“Technology”) was incorporated on October 14, 2009 under the laws of Florida.  Renuell Int’l, Inc. and NueEarth, Inc., Technology’s wholly owned subsidiaries and Technology, collectively, are referred to here-in as the “Company”, a development stage company.  The Company is engaged in developing market entry technology products and services into early and mainstream technology products and services.  Through our subsidiaries, we are focused on developing and manufacturing a line of technologically advanced skin care products and providing environmental management solutions that use electron particle accelerator technology.


Principles of Consolidation


The consolidated financial statements include the accounts of Technology Applications International Corporation and its wholly owned subsidiaries, Renuell Int’l, Inc. and NueEarth, Inc.  All significant inter-company accounts and transactions have been eliminated in consolidation.


Basis of Presentation and Going Concern Considerations


The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2014.


For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.


The accompanying financial statements have been presented on the basis that it is a going concern which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs.  The Company’s ability to continue as a going concern is highly dependent upon management’s ability to increase near-term operating cash flows and obtain additional working capital through the issuance of debt and or equity.  If the Company is unable to obtain adequate capital, it could be forced to cease operations.


These consolidated financial statements present the financial condition, and results of operations and cash flows of the operating companies.


Development Stage Risk


Since its inception, the Company has been dependent upon the receipt of capital investment to fund its operating activities.  In addition to the normal risks associated with a new business venture, there can be no assurance that the Company’s business plans will be successfully executed.  The Company’s ability to execute its business plans is dependent on its ability to obtain additional debt and equity financing and achieving a profitable level of operations.  There can be no assurance that sufficient financing will be obtained or that we will achieve a profitable level of operations.




7



The Company has minimal revenues generated from operations due to the sale of sample products.  Accordingly, the Company’s activities have been accounted for as those of a “Development Stage Enterprise” as set forth in Accounting Standards Codification (“ASC”) 915 “Development Stage Entities”.  Among the disclosures required are that the Company’s financial statements be identified as those of a development stage company and that the statements of operations, shareholders’ equity / (deficit) and cash flows disclose activity since the date of the Company’s inception.


2.

Inventories


Inventories are stated at the lower of cost or market value.  The Company reduces the value of its inventories to market value when the value is believed to be less than the cost of the item.


 

March

31, 2014

 

December 31

 2013

 

 

 

 

Raw materials

$

-

 

$

-

Work-in-process

-

 

-

Finished goods

88,420

 

70,862

 

 

 

 

     Total Inventories

$

88,420

 

$

70,862



No reserves for inventory have been deemed necessary at March 31, 2014.


3.

Machinery and Equipment


Machinery and equipment are recorded at cost.  Expenditures for maintenance and repairs are charged to earnings as incurred whereas additions, renewals and betterments are capitalized.  When machinery and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations.  Depreciation of machinery and equipment is provided using the straight-line method over the assets estimated useful lives of approximately 5 to 7 years.  Leasehold improvements, if any, are amortized on a straight-line basis over the term of the lease or the estimated useful lives, whichever is shorter.


Machinery and equipment, as of March 31, 2014 and December 31, 2013, consisted of the following:


 

Estimated

Useful Lives

March

31, 2014

 

December

31, 2013

 

 

 

 

 

Computer Equipment

3 Years

$

4,162 

 

$

4,162 

Machinery and equipment

5 Years

13,418 

 

13,418 

Furniture and fixtures

7 Years

14,073 

 

14,073 

Accumulated depreciation

 

(13,464)

 

(12,282)

 

 

$

18,189 

 

$

19,371 



Depreciation expense for the three month periods ended March 31, 2014 and 2013 were $1,182 and $993, respectively.


4.

Convertible Debenture


During December 2011, the Company received $100,000 as a deposit for entering into a distribution agreement.  On March 22, 2012, the Company converted the $100,000 deposit into a convertible debenture.  The convertible debenture bears interest at a rate of five-percent (5%) per annum and is payable March 21, 2014.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share.  In February 2014, the Noteholder elected to convert $84,143 (including accrued interest of $9,143) into 168,285 shares of the Company’s Common Stock at $0.50 per share. The Company issued 218,285 warrants to purchase 218,285 shares of



8



common stock exercisable at $1.00 per share. As of March 31, 2013, 218,285 warrants are not exercised. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014).


On September 25, 2012, the Company issued a $100,000 convertible debenture.  The convertible debenture bears interest at a rate of five-percent (5%) per annum and is payable September 20, 2013.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. This convertible debenture extended 360 days on September 21, 2013. In December 2013, the Noteholder elected to convert $25,000 into 50,000 shares of the Company’s Common Stock at $0.50 per share.  In February 2014, the Noteholder elected to convert $88,273 (including accrued interest of $13,273) into 176,515 shares of the Company’s Common Stock at $0.50 per share. The Company issued 226,515 warrants to purchase 226,515 shares of common stock exercisable at $1.00 per share. As of March 31, 2013, 226,515 warrants are not exercised. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014).


On May 23, May 31, June 10, July 29, August 14, and September 25, 2013, the Company issued a $10,000, $10,000, $25,000, $4,000, $50,000 and $20,000 convertible debentures, respectively.  The convertible debentures bear interest at a rate of ten-percent (10%) per annum and is payable May 18, May 26, June 5, 2014, July 24, august 9, September 20, 2014, respectively.  At the Holder’s option, principle and unpaid accrued interest shall be convertible into common stock at a rate of $0.50 per share.  In addition to the common stock, the Holder shall receive warrants to purchase an equal number of shares of common stock exercisable at $1.00 per share.  These warrants expire at the earlier of 180 days after the common stock commences quotation on the OTC Bulletin Board or one-year from exercise. In February 2014, the Noteholder elected to convert $110,866 (including accrued interest of $6,866) into 220,785 shares of the Company’s Common Stock at $0.50 per share. The Company issued 220,785 warrants to purchase 220,785 shares of common stock exercisable at $1.00 per share. As of March 31, 2013, 220,785 warrants are not exercised. Warrant expiration date is September 21, 2014 (180 days after the Company’s common stock commences quotation on the OTC Bulletin Board (March 25, 2014). As of March31, 2014, the convertible debenture was $21,025 (including accrued interest of $1,025). In April 2014, the Noteholder elected to convert $20,767 (including accrued interest of $767) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share.


The following table reflects the components of the initial allocation:


Compound derivative

$ 521,452

Convertible debentures payable, net of discount

-

Interest expense

197,452

 

$ 324,000



The Compound derivative comprises certain derivative features embedded in the host convertible debenture contracts including the conversion feature and warrants both of which contain anti-dilution protections.  These instruments were combined into one compound derivative and bifurcated from the host instrument at fair value.  The Company applied the Black-Scholes Merton valuation technique to fair value these derivatives because this technique embodies all of the assumptions necessary to fair value these compound derivative instruments.


Since the derivative financial instruments are required to be recorded, both initially, and subsequently, at fair value, there were insufficient proceeds to allocate any amount to the convertible debentures and, accordingly, it has no carrying value on the date of inception.  Additionally, proceeds were insufficient to record the fair values of the derivative financial instruments, resulting in initial interest expense of $197,452.  It should be noted that the derivative instruments will be adjusted to fair value at each reporting date.  As the Company does not have historical volatility data for its own stock, the expected volatility was based upon the Company’s peer group in the industry in which it does business.  Fair values are highly influenced by the trading stock price and volatility of the peer group, changes in our credit risk and market interest rates.


The company amortizes the discount on the convertible debentures resulting from the initial allocation over the term of the convertible debt instruments using the effective method.  Amortization expense arising from this method for the years ended March 31, 2014 and December 31, 2013 amounted to $66,289 and $182,197 which have been



9



included as a component of interest expense. During the quarter ended March 31, 2014 the Company converted $254,000 of the convertible debt into 485,000 shares of the Company’s common stock. The balance of the convertible debt as of March 31, 2014 is $19,999 with a debt discount of $9,611, for net convertible debt of $10,388.


5.

Capital Stock


On October 14, 2009, the Company issued 3,000,000 shares of common stock for $3,000.


On August 26, 2010, the Company issued 100,000 shares of its common stock to purchase equipment.


On October 20, 2011, the Company issued 101,800,000 shares of its common stock as payment for cancellation of debt for part of the amount due to its related party.


On October 28, 2011, the Company issued 5,727,000 shares of its common stock to a consultant as payment for services rendered.


On November 8, 2011, the Company issued 5,591,000 shares of its common stock to a consultant as payment for services rendered.


During November and December 2011, the Company issued 236,000 shares of its common stock through a private placement to several investors for total cash consideration of $118,000.


During January and February 2012, the Company issued 794,000 shares of its common stock through a private placement for total cash consideration of $397,000.


In December 31, 2013, the Company issued 100,000 shares of its common stock at $0.50 for conversion of convertible debenture of $50,000.


In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debenture of $254,000.


In March 2014, the Company issued 485,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $234,000. Also, the Company issued 485,000 warrants to purchase 485,000 shares of common stock exercisable at $1.00 per share.


In March 2014, the Company entered into stock subscription agreement of 133,000 shares at $0.50 per share. The Company recorded $66,500 as subscription receivable. The Company issued 133,000 warrants to purchase to purchase 133,000 shares of common stock exercisable at $1.00 per share.


Due to a ratchet provision, the warrants issued during the period were accounted for as a derivative and fair valued using the Black Scholes valuation model. The initial valuation was $367,916 including $251,814 of amounts that exceeded the proceeds of the common stock and were therefore expensed immediately to derivative expense.


Stock Purchase Warrants


In conjunction with the Private Placement Memorandum dated October 28, 2011, the Company is offering up to 10,000 Units.  Each Unit consists of 1,000 shares of common stock priced at $0.50 per share and one Class A Warrant to purchase 1,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance.


Warrants to purchase up to1,030,000 shares of common stock were issued in accordance with the Private Placement Memorandum stated above.  Of these issuances, warrants to purchase up to 236,000 shares and 794,000 shares of common stock expired during 2012 and 2013.  


In conjunction with the Private Placement Memorandum dated February 13, 2013, the Company is offering up to 3,000,000 units.  Each unit consists of 1 share of common stock priced at $1.00 and one Class A Warrant to purchase 1 share of common stock with an exercise price of $1.50 per share.  These warrants expire on the earlier of (i) 180 days after the common stock commences quotation on the OTC Bulletin Board or (ii) one year after the date of issuance. No issuances have been sold from this offering as of December 31, 2013.




10



In December 2013, the Noteholder elected to convert $50,000 into 100,000 shares of the Company’s Common Stock at $0.50 per share.  The Company issued 100,000 warrants to purchase 100,000 shares of common stock exercisable at $1.00 per share.  


The following table summarizes all warrant activity for the period ended March 31, 2014 and December 31, 2013:


 

 

Shares

 

Weighted-Average Exercise Price Per Share

Exercisable at December 31, 2013

 

100,000

 

1.00

Granted

 

1,149,000

 

1.00

Expired

 

100,000

 

 

Outstanding, March 31, 2014

 

1,149,000

 

1.00



6.

Fair Value Measurements



On a recurring basis, we measure certain financial assets and liabilities based upon the fair value hierarchy.  The following table presents information about the Company’s liabilities measured at fair value as of March 31, 2014 and December 31, 2013:



 

 

Level 1

 

Level 2

 

Level 3

 

Fair Value at

March 31, 2014

Liabilities

 

 

 

 

 

 

 

 

Derivative Liability

 

-

 

-

 

$

2,557,054

 

$

2,557,054


 

 

Level 1

 

Level 2

 

Level 3

 

Fair Value at

December 31, 2013

Liabilities

 

 

 

 

 

 

 

 

Derivative Liability

 

-

 

-

 

$

349,940

 

$

349,940



The fair value changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), relate solely to the derivative liability as follows:


Balance as of December 31, 2012

 

$

276,000 

Derivative liability recorded

 

266,912 

Adjustment due to conversion

 

(31,080)

Fair value adjustment

 

(161892)

Balance at December 31, 2013

 

349,940 

Adjustment due to conversion

 

(87,599)

New warrant issued with stock

 

367,916 

Fair value adjustment

 

1,926,797 

Balance at March 31, 2014

 

2,557,054 



7.

Related Parties


An affiliate of the Company, an entity owned by the Company’s president, has been funding operations of the Company by making payments directly to third parties or advancing monies to the Company.  These amounts bear no interest and are payable on demand.  Amounts due to the affiliate at March 31, 2014 and December 31, 2013 are approximately 341,000 and $237,000, respectively.


During June 2012, the Company borrowed $125,000 from an affiliate.  The loan bears interest at 10% per annum and is unsecured and payable upon demand.  The Company has paid $36,120 towards the loan amount.  The outstanding balance at March 31, 2014 and December 31, 2013 is $77,401.




11



8.

Subsequent Events


Pursuant to Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that have occurred from January 1, 2014 through the filing with the SEC.  The Company did not have any material recognizable subsequent events during this period.


On April 2014, the Noteholder elected to convert $20,767 (including accrued interest of $767) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share.


On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 180 days after stock issuance date.


On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 180 days after stock issuance date.



12



ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATION


FORWARD-LOOKING STATEMENTS


This Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) contains forward-looking statements that involve known and unknown risks, significant uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, or implied, by those forward-looking statements. You can identify forward-looking statements by the use of the words may, will, should, could, expects, plans, anticipates, believes, estimates, predicts, intends, potential, proposed, or continue or the negative of those terms. These statements are only predictions. In evaluating these statements, you should consider various factors which may cause our actual results to differ materially from any forward-looking statements. Although we believe that the exceptions reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


RESULTS OF OPERATIONS


Working Capital


 

March 31,

2014

$

December 31, 2013

$

Current Assets

315,641

84,662

Current Liabilities

3,337,065

1,207,335

Working Capital (Deficit)

(3,021,424)

(1,122,673)



Cash Flows


 

March 31,

2014

$

March 31,

2013

$

Cash Flows used in Operating Activities

(123,856)

(100,144)

Cash Flows provided used in Financing Activities

(337,277)

(7,819)

Cash Flows used in Investing Activities

-

-

Net Increase (decrease) in Cash During Period

213,421

(107,963)



Results for the Quarter Ended March 31, 2014 Compared to the Quarter Ended March 31, 2013


Operating Revenues


The Company’s revenues were $2,268 for the three months ended March 31, 2014 compared to $10,047 for the same period in 2013.  This represents a decrease of $7,779 or 77% which is attributable to the Company’s efforts to develop the product and create relationships with major retailers.


Cost of Revenues


The Company’s cost of revenues was $2,920 for the three months ended March 31, 2014 compared to $5,449 for the same period in 2013.  This represents a decrease of $2,529 or 46% which is directly attributable to the decrease in revenues.


Gross Profit


For the three months ended March 31, 2014, the Company’s gross profit decreased by $5,250 or 114% from $4,598 for the same period in 2013.  As a percentage of sales, gross profit was (29)%.




13



General and Administrative Expenses


General and administrative expenses consisted primarily of consulting fees, professional fees, travel and meals and entertainment relating to being a public company.  For the three months ended March 31, 2014 and March 31, 2013, general and administrative expenses decreased to $128,728 from $138,658 for the same period in 2013 representing a decrease of $9,930 or $7.1%.  The change is primarily attributable to decreases in consulting and general administrative expenses normal for a publicly reporting company.


Other Income (Expense)


Other income (expense) consisted of a loss on derivative valuation, derivative expense and interest expense.  The loss on derivative valuation is directly attributable to an increase in derivatives related to the warrants issued with common stock during the quarter, and the change in fair value of the derivative liability from December 31, 2013, through March 31, 2014.  The increase in derivative expense relates to the warrants issued during the period. Interest expense is primarily attributable to the accretion of the debt discount on convertible debentures for the three months ended March 31, 2014.  There was a 25,000 loss on derivative valuation and $29,374 of interest expense for the same period in 2013.


Net Loss


Our net loss for the three months ended March 31, 2014, was $(2,387,773) compared with a net loss of $(188,434) for the three months ended March 31, 2013, an increase of $2,199,339 or 1167%.  The net loss is influenced by the matters discussed above.


Results for the Period from October 14, 2009 (inception of development stage) Through March 31, 2014.


Operating Revenues


The Company’s revenues were $2,268 for the three months ended March 31, 2014, compared to $63,306 for the period from October 14, 2009 (inception of development stage) through March 31, 2014.


Cost of Revenues


The Company’s cost of revenue was $2,920 for the three months ended March 31, 2014 compared to $34,219 for the period from October 14, 2009 (inception of development stage) through March 31, 2014.


Gross Profit


For the three months ended March 31, 2014, the Company’s gross profit was $(652) compared to $29,087 for the period from October 14, 2009 (inception of development stage) through March 31, 2014.


General and Administrative Expenses


General and administrative expenses consisted primarily of consulting fees, professional fees, travel and meals and entertainment.  For the three months ended March 31, 2014, general and administrative expenses were $128,728 compared to $1,621,222 for the period from October 14, 2009 (inception of development stage) through March 31, 2014.


Other Income (Expense)


Other income (expense) for the period October 14, 2009 (inception) through March 31, 2014 was $(2,258,393).  Other income (expense) consisted of a loss on derivative valuation, derivative expense and interest expense.  The loss on derivative valuation is directly attributable to an increase in derivatives related to the warrants issued with common stock during the quarter, and the change in fair value of the derivative liability from date of issuance in 2012, through March 31, 2014.  The increase in derivative expense relates to the warrants issued during the period. Interest expense is primarily attributable to the accretion of the debt discount on convertible debentures.  


Net Loss


Net loss for the period from October 14, 2009 (inception of development stage) through March 31, 2014 was $(4,192,682).  The net loss for this period was primarily related to general and administrative expenses exceeding the amount of revenues for the period indicated.



14




Liquidity and Capital Resources


The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan.  Since its inception, the Company has been funded by related parties through capital investment and borrowing of funds.


At March 31, 2014, the Company had total current assets of $315,641 compared to $84,662 at December 31, 2013.  Current assets consisted primarily of cash, inventories and deposits, the increase in cash and total assets were attributed to equity financing of $234,000, of which a large portion remained unspent as of the period end date.


At March 31, 2014, the Company had total current liabilities of $3,337,065 compared to $1,207,335 at December 31, 2013.  Current liabilities consisted primarily of the derivative liability, accounts payable and accrued expenses, loans and advances from a related party and convertible debentures.


We had negative working capital of $(3,021,424) as of March 31, 2014 compared to $(1,122,673) as of December 31, 2013, a decrease of $(1,898,751) or 169%.


Cashflow from Operating Activities


During the three months ended March 31, 2014, cash used in operating activities was $(123,856) compared to $(100,144) for the three months ended March 31, 2013. The increase in the amounts of cash used for operating activities was primarily due to the increased net loss, offset by loss on derivative valuation, derivative expense, amortization of discount on convertible notes and higher amounts of skin care products being purchased for inventory and a related decrease in accounts payable and accrued expenses.


Cashflow from Investing Activities


During the three months ended March 31, 2014 cash used in investing activities was $0 compared to $0 for the three months ended March 31, 2013.


Cashflow from Financing Activities


During the three months ended March 31, 2014, cash used in financing activity was $337,277 compared to $(7,819) being provided during the three months ended March 31, 2013.  The increase in cash provided by financing activities is due to the Company receiving proceeds of $234,000 from issuance of stock and warrants, and proceeds from advances from related parties.


Going Concern


We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive acquisitions and activities. For these reasons, our auditors stated in their report on our audited financial statements that there is substantial doubt about our ability to continue as a going concern without further financing.


Future Financings


We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund our operations and other activities.


Impact of Inflation


We believe that the rate of inflation has had a negligible effect on our operations.


Off-Balance Sheet Arrangements


We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.




15




Critical Accounting Policies


Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.


We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.


Recently Issued Accounting Pronouncements


The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK


We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.


ITEM 4. CONTROLS AND PROCEDURES


Evaluation of Disclosure Controls and Procedures


Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management carried out an evaluation under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 ("Exchange Act").  Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were not effective as of March 31, 2014, due to the material weaknesses resulting from the Board of Directors not currently having any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K, and controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements.  Please refer to our Annual Report on Form 10-K as filed with the SEC on April 15, 2014 and the Amendment to the Form 10-K filed with the SEC on April 24, 2014, for a complete discussion relating to the foregoing evaluation of Disclosures and Procedures.

 

Changes in Internal Control over Financial Reporting

 

Our management has also evaluated our internal control over financial reporting, and there have been no significant changes in our internal controls or in other factors that could significantly affect those controls subsequent to the date of our last evaluation.

 

The Company is not required by current SEC rules to include, and does not include, an auditor's attestation report. The Company's registered public accounting firm has not attested to Management's reports on the Company's internal control over financial reporting.




16



PART II - OTHER INFORMATION


ITEM 1.  LEGAL PROCEEDINGS


We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.


ITEM 1A.  RISK FACTORS


We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.


ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


1. Quarterly Issuances:


From January 1, 2014 to March 31, 2014, the holders of convertible notes converted a total of $281,539 of principal and interest into 565,585 shares of our common stock at $0.50 per share.

In February 2014, the Company issued 565,615 shares of its common stock at $0.50 for conversion of convertible debenture of $254,000.


In March 2014, the Company issued 485,000 shares of its common stock at $0.50 through a private placement for total cash consideration of $234,000. Also, Company issued 485,000 warrants to purchase 485,000 shares of common stock exercisable at $1.00 per share.


In March 2014, the Company entered into stock subscription agreement of 133,000 shares at $0.50 per share. The Company recorded $66,500 as subscription receivable. The Company issued 133,000 warrants to purchase to purchase 133,000 shares of common stock exercisable at $1.00 per share.


These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.


2. Subsequent Issuances:


On April 2014, the Noteholder elected to convert $20,767 (including accrued interest of $767) into 41,534 shares of the Company’s Common Stock at $0.50 per share. The Company issued 41,534 warrants to purchase 41,534 shares of common stock exercisable at $1.00 per share.


On April 3, 2014, the Company entered stock subscription agreement of 5,000 shares at $1.00 per share with 5,000 warrants to purchase 5,000 shares of common stock with an exercise price of $2.00 per share.  These warrants expire 180 days after stock issuance date.


On April 16, 2014, the Company entered stock subscription agreement of 20,000 shares at $0.50 per share with 20,000 warrants to purchase 20,000 shares of common stock with an exercise price of $1.00 per share.  These warrants expire 180 days after stock issuance date.


These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.


ITEM 3. DEFAULTS UPON SENIOR SECURITIES


None.



17




ITEM 4. MINE SAFETY DISCLOSURES


Not applicable.


ITEM 5. OTHER INFORMATION


None.


ITEM 6. EXHIBITS


Exhibit

 

 

 

Number

Description of Exhibit

 

Filing

 

 

 

 

3.1

Articles of Incorporation

 

Filed with the SEC on January 19, 2010 as part of the Company’s Registration of Securities on Form 10-12G.

3.1(a)

Restated Articles of Incorporation

 

Filed with the SEC on April 18, 2011 as part of the Company’s Current Report on Form 8-K.

3.2

Bylaws

 

Filed with the SEC on January 19, 2010 as part of the Company’s Registration of Securities on Form 10-12G.

3.2(a)

Amended Bylaws

 

Filed with the SEC on April 18, 2011 as part of the Company’s Current Report on Form 8-K.

10.1

Lease between Brickell Bay Tower Ltd., Inc. and Raj Ventures, Inc. dated October 18, 2010.

 

Filed with the SEC on March 28, 2010 as part of the Company’s Annual Report on Form 10-K.

10.2

Share Purchase Agreement by and among Raj Ventures, Inc., Willowhuasca Wellness, Inc., and Raj Ventures Funding, Inc., dated April 12, 2010.

 

Filed with the SEC on April 12, 2010 as part of the Company’s Current Report on Form 8-K.

10.3

Bill of Sale and Assignment between Raj Ventures, Inc., and High Voltage Environmental Applications, Inc., dated as of August 26, 2010.

 

Filed with the SEC on September 1, 2010 as part of the Company’s Current Report on Form 8-K.

10.4

Promissory Note between the Company and Joe-Val, Inc., dated March 27, 2012.

 

Filed with the SEC on March 27, 2012 as part of the Company’s Current Report on Form 8-K.

10.5

Promissory Note between the Company and Coast To Coast Equity Group, Inc., dated June 25, 2012.

 

Filed with the SEC on August 20, 2012 as part of the Company’s Quarterly Report on Form 10-Q.

10.6

Convertible debenture between the Company and Shane Case, dated September 26, 2012.

 

Filed with the SEC on November 19, 2012 as part of the Company’s Quarterly Report on Form 10-Q.

10.7

Distribution Agreement between Regenetech, Inc. and Renuéll Int’l, Inc., dated December 29, 2011 and Amended on December 13, 2012.

 

Filed with the SEC on January 17, 2013 as part of the Company’s S-1/A...

10.8

Form of Subscription Agreement.

 

Filed with the SEC on November 29, 2012 as part of the Company’s S-1/A.

10.9

Consulting Agreement between the Company and John Stickler.

 

Filed with the SEC on December, 27, 2012 as part of the Company’s S-1/A

10.10

Co-License Agreement by and between Technology Applications International Corporation and the National Aeronautics and Space Administration, dated September 30, 2013.

 

Filed with the SEC on October 4, 2013, as part of our Current Report on Form 8-K.

16.1

Letter from Lake of Associates CPA’s LLC, dated March 12, 2013.

 

Filed with the SEC on March 14, 2013 as part of the Company’s Current Report on Form 8-K.

21.1

List of Subsidiaries

 

Filed with the SEC on April 16, 2012 as part of the Company’s Annual Report on Form 10-K.

31.01

Certification of Principal Executive Officer Pursuant to Rule 13a-14

 

Filed herewith.

31.02

Certification of Principal Financial Officer Pursuant to Rule 13a-14

 

Filed herewith.

32.01

Certification of CEO and CFO Pursuant to Section 906 of the Sarbanes-Oxley Act

 

Filed herewith.

101.INS*

XBRL Instance Document

 

Furnished herewith.

101.SCH*

XBRL Taxonomy Extension Schema Document

 

Furnished herewith.

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

 

Furnished herewith.

101.LAB*

XBRL Taxonomy Extension Labels Linkbase Document

 

Furnished herewith.

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

 

Furnished herewith.

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

 

Furnished herewith.


*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.




18



SIGNATURES


In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


TECHNOLOGY APPLICATIONS INTERNATIONAL CORPORATION



Dated: May 20, 2014

/s/ Charles J. Scimeca

By: Charles J. Scimeca

Its: President, Principal Executive Officer & Principal Financial Officer (Principal Accounting Officer)




Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated:



Dated: May 20, 2014

/s/ Charles J. Scimeca

Charles J. Scimeca – Director


Dated: May 20, 2014

/s/ John Stickler

John Stickler – Director



19